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OBJECTIVES: Iatrogenic chronic pain is increasingly recognized
as a major adverse outcome after inguinal hernia repair. In order
to assess chronic post-herniorrhaphy pain, we developed the 18-
item Inguinal Pain Questionnaire (IPQ). The aim of the present
study was to test its validity and reliability and explore the preva-
lence of long term pain as determined by the questionnaire in a
sample from the population-based Swedish Hernia Register.
METHODS: Validity was tested in 100 patients who received
the IPQ and the Brief Pain Inventory (BPI) 1 and 4 weeks after
surgery (Group A). The reliability was tested in 100 patients who
received the IPQ on two occasions one month apart 3 years after
operation (Group B). From the Swedish Hernia Register 2853
operated 2000 were requested to ﬁll in IPQ by mail. RESULTS:
As an indication of construct validity, a signiﬁcant (p < 0.001)
decrease in IPQ-rated pain intensity was observed in the ﬁrst 4
weeks after surgery. Signiﬁcant (p < 0.05) correlations with cor-
responding BPI pain intensity items corroborated the criterion
validity. The rate of logical incoherence did not exceed 5.5% for
any item. Kappa values in the test-retest one month apart in
group B were higher than 0.5 for all but three items, indicating
acceptable reliability. Cronbachs alpha was 0.83 for questions
on pain intensity and 0.51 for interference with daily activities.
After two reminders, 2456 patients (86%), in the sample from
the Hernia Register had responded to the questionnaire. In
response to a question about “worst perceived pain last week”,
758 patients (31%) reported pain to some extent. In 144 cases
(6%) the pain interfered with daily activities. CONCLUSION:
The validity and reliability is sufﬁcient to make IPQ a useful
instrument in the routine assessment of post-herniorrhaphy pain.
Disabling pain was found to be a widespread problem 3 years
after surgery.
RESPIRATORY DISEASES—Clinical Outcomes Studies
PRS1
BURDEN OF CONCOMITANT ASTHMA AND COPD IN A
MEDICAID POPULATION
Shaya FT1, Du D1,Wang J1,Akazawa M2, Blanchette CM3,
Mapel DW4
1University of Maryland School of Pharmacy, Baltimore, MD, USA,
2GlaxoSmithKline / University of North Carolina at Chapel Hill, RTP,
NC, USA, 3GlaxoSmithKline, RTP, NC, USA, 4Lovelace Clinic
Foundation, Albuquerque, NM, USA
OBJECTIVES: Asthma and chronic obstructive pulmonary
disease (COPD) present health concerns and an economic burden
for patients and managed care plans. This study compares uti-
lization outcomes in patients with COPD, asthma or co-
occurring COPD and asthma in a Medicaid population.
METHODS: We queried all medical and pharmacy claims of
Medicaid patients with COPD and/or asthma ﬁled between
January 1, 20001 and December 31, 2003, from encounter data.
COPD patients were identiﬁed based on at least one claim with
ICD-9 codes 491, 492, 496, and asthma patients on the basis of
ICD-9 code 493 as primary, secondary or tertiary diagnosis. We
analyzed annual utilization attributable to COPD and/or asthma,
and compared relative utilization of hospitalizations, physician,
outpatient and emergency room visits as well as drug prescrip-
tions. RESULTS: The analysis included a total of 3455 COPD,
3072 asthma and 2604 COPD/asthma patients, and showed 
statistically signiﬁcant differences in the use of services.
COPD/asthma co-occurring disease has higher utilization of any
service type than either disease alone. Compared with asthma,
COPD has higher use of hospitalizations (p < 0.0001), and less
out-patient services (p < 0.0001) and outpatient-emergency visits
(p < 0.0001). Logistic regression results suggest that COPD
patients were 16%-51% more likely to use physician visits (OR
= 1.16, 95% CI: 1.01–1.34) and inpatient services (OR = 1.51
95% CI: 1.31–1.74) and less likely to use out-patient services
(OR = 0.40 95% CI: 0.35–0.46). COPD and asthma co-occur-
ring patients had higher utilization of all services compared with
asthma patients. CONCLUSION: Our data suggest that COPD
and COPD/asthma co-occurring patients were sicker and used
more medical services than asthma patients.
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OBJECTIVES: To review the clinical outcomes of patients hos-
pitalized with chronic obstructive pulmonary disease (COPD)
acute exacerbations in Singapore and to describe the impact of
evidence-based management programs. METHODS: A retro-
spective review was designed for COPD exacerbations patients
admitted from year 2000 to 2005 in three public hospitals in 
Singapore. Adult patients aged 40 years and above with COPD
as the primary reason for hospitalization were retrieved from
computerized database. The outcomes studied included average
hospital length of stay (LOS), in-hospital mortality rate and read-
mission rates within 15 days, 30 days and 90 days. Univariate
ANOVA and Chi-square test, multivariate regression models and
trend analysis were applied to generate statistical results.
RESULTS: Among all 2996 COPD patients, 78.8% were male
(95% CI: 77.3–80.3%). Chinese were about 82.4% (95% C.I.:
81.0–83.8%), Indian 6.6% (95% CI: 5.7–7.5%), and Malay
7.8% (95% CI: 6.8–8.8%). Patients aged 60 and above were the
major population, taking up to 90.4% (95% CI: 89.3–91.5%).
From 2000 to 2005 there were signiﬁcant declines in LOS (6–3
days; p < 0.001), and mortality (12.1–3.7%; p < 0.001) rates.
There were also signiﬁcant reduction in readmission rates at 90
days (22.5–13.6%; p < 0.001) but not at 30 days (11.8–8.6%;
p = 0.076) or 15 days (6.5–6.0%; p = 0.218). By multivariate
regression, by controlling other factors, age is a risk factor for
longer hospital LOS (p = 0.02). Elder patients are also more dan-
gerous on in-hospital death (p < 0.001) and readmission within
90 days (p = 0.043). All the readmission rates for male patients
were signiﬁcantly higher than females (p = 0.002, p < 0.001 and
p < 0.001 for 15, 30, and 90 days respectively). CONCLUSION:
In summary, although the study suffers from several limitations,
i.e. lack of controls, confounded by disease severity etc, it has
shown that implementation of goal directed management pro-
grams in COPD patients was associated with positive trends in
reduced hospitalization, hospital mortality and readmission
rates.
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OBJECTIVES: The costs of respiratory tract infections are con-
siderable. The purpose of this study was to estimate the direct
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and incremental costs of three different types of respiratory infec-
tions: acute sinusitis (AS), acute otitis media (AOM), and com-
munity-acquired pneumonia (CAP). METHODS: Data were
from the Marketscan claims databases July–December 2004.
Respiratory disease episodes were constructed via ICD9 codes
on an index and surrounding claims. The antibiotics most fre-
quently prescribed initially for each type of infection were iden-
tiﬁed. Logistic regression estimated a propensity score for each
patient; which was the predicted probability of using a reference
drug, telithromycin. Patients were matched according to this
probability and exponential conditional means models (ECM)
were speciﬁed, controlling signiﬁcant variables after the propen-
sity score matching (demographics and comorbidities). These
models allowed incremental costs to be estimated for treatment
with the reference drug, telithromycin, relative to other antibi-
otics. RESULTS: There were 86,232 AS, 71,884 AOM (10%
were among patients under 18) and 5236 CAP episodes. The
most commonly used antibiotic for initial treatment was amox-
icillin for AOM, and AS and azithromycin for CAP. Total costs
were $182 for AS, $192 for AOM and $897 for CAP. The
highest incremental cost saving associated with telithromycin
was relative to moxiﬂoxacin in CAP ($484; p < 0.001). The
highest incremental cost saving with another antibiotic relative
to telithromycin was $23.43 (p < 0.001) in the AS episodes ini-
tiated with azithromycin. CONCLUSION: The multivariate
results showed that after propensity matching and controlling for
intra-episode differences, that direct costs did indeed vary by the
initiating antibiotic. It is of interest to note that the results did
not uniformly favor one agent over another. Although different
antibiotics may be included in the same drug class, there are
clearly differentials between these drugs to consider not only
clinically, but also for ﬁnancial implications as well.
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OBJECTIVES: The purpose of the study was to evaluate eco-
nomic and health consequences of ﬁrst line antibiotics treatment
for inpatient therapy in Mexican patients with acute exacerba-
tions of chronic bronchitis (AECB) from the health care payer’s
perspective. METHODS: A cost—effectiveness assessment was
performed employing two economic models. First, a three-month
decision tree model was used to compare costs and effectiveness
associated to acute exacerbations treatments. Second, a one-year
Markov model was created to compare costs and effectiveness
associated to AECB recurrences. Model comparators were: gemi-
ﬂoxacin 320 mg/day, moxiﬂoxacin 400 mg/day, levoﬂoxacin 
500 mg/day, ceftriaxone 1 gr/day, gatiﬂoxacin 400 mg/day, clar-
ithromycin 1000 mg/day and cefuroxime 1000 mg/day. The
effectiveness measures were the % of clinical success and the
number of free months of recurrences/hospitalizations. Resource
use data was obtained from hospital records inside the General
Regional Hospital No. 1 “Gabriel Mancera” at the Social Secu-
rity Mexican Institute (IMSS) in Mexico City (n = 117). All drug
prices and resource use costs were taken from ofﬁcial institu-
tional databases from the IMSS. One-way and probabilistic sen-
sitivity analyses were performed and components analyses were
elaborated. RESULTS: Gemiﬂoxacin showed the lowest expected
costs (US$2750.2); the highest % of clinical success among all
alternatives (97.5%) and the shorter hospitalization stay length
(approximately 6.1-days). The total days reduction generated 
by gemiﬂoxacin could reduce total hospitalization costs in
$US1269.5 per acute exacerbation. Markov model results for
free months of recurrences showed that gemiﬂoxacin ﬁrst line
therapy for AECB could give patients in average 11.1-free
months of recurrences/hospitalizations followed of ceftriaxone
(10.9-months) and moxiﬂoxacin (10.5-months). The results were
robust to ﬁrst-order Monte Carlo simulations and acceptability
curves. CONCLUSION: Gemiﬂoxacin is the most cost effective
ﬁrst line treatment for inpatients with AEBC, because its high
effectiveness, signiﬁcant inpatients day’s reduction and more free
months of recurrences. These results could be used by Mexican
decision-makers to generate future cost-containment strategies.
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OBJECTIVES: The purpose of the study was to estimate the
incremental cost-effectiveness ratios (ICER) among the ﬁrst-
line antibiotics for the inpatient treatment of Mexican patients
with community acquired pneumonia (CAP) from the health 
care payer’s perspective. METHODS: A cost—effectiveness
analysis was performed with the aid of a decision tree model.
The model had a two-month period to assess economic and 
clinical consequences of seven ﬁrst-line antibiotics used in the
study: Gemiﬂoxacin 320 mg/day, Clarithromycin 1000 mg/day, 
Levoﬂoxacin 500 mg/day, Gatiﬂoxacin 400 mg/day, Ceftriaxone
1 gr/day, Cefuroxime 1500 mg/day and Moxiﬂoxacin 400 mg/
day. Adverse events of each therapy were considered (rash, diar-
rhea, dizziness, vomits, chill and head pain). Resource use data
was obtained from hospital records from the General Regional
Hospital No. 1 “Gabriel Mancera” at the Social Security
Mexican Institute (IMSS) in Mexico City (n = 94). All drug prices
and unit costs were taken from ofﬁcial institutional databases
within the IMSS. Effectiveness measures used in the model was
the % of therapeutic success among the multiple antibiotics.
One-way and probabilistic sensitivity analyses were performed
and acceptability curves were constructed. RESULTS: Gemi-
ﬂoxacin showed the lowest average health care costs in inpatient
treatment (US$ 2389.8) due to a signiﬁcant reduction in the 
hospitalization days (approximately 4.61 days in average per
patient). The length of stay reduction was associated with the
shorter treatment of gemiﬂoxacin (ﬁve-days). Gemiﬂoxacin
showed the highest effectiveness (95.3%) followed by clar-
ithromycin (94.3%); levoﬂoxacin (94.0%); gatiﬂoxacin
(92.0%); ceftriazone (91.3%); cefuroxime (90.0%) and moxi-
ﬂoxacin (86.5%). The ICERxs for all treatments were dominated
by gemiﬂoxacin. First-order Monte Carlo simulations showed
the same results. CONCLUSION: Gemiﬂoxacin was the most
cost effective ﬁrst line treatment for hospitalized patients with
CAP, especially, because it’s high effectiveness and its signiﬁcant
inpatient-stay length reduction.
PRS6
EVALUATING THE COST-EFFECTIVENESS OF TIOTROPIUM IN
THE TREATMENT OF MODERATE CHRONIC OBSTRUCTIVE
PULMONARY DISEASE
Naik S, Kamal KM, Keys P, Mattei T
Duquesne University, Pittsburgh, PA, USA
